Goodrx Holdings, Inc. Stock Price, News & Analysis

GoodRx (NASDAQ:GDRX), the leading U.S. medication savings platform, reported Q2 2025 results with revenue of $203.1 million, up 1% year-over-year. The company achieved net income of $12.8 million with a 6.3% margin and Adjusted EBITDA of $69.4 million with a 34.2% margin.

While Pharma manufacturer solutions revenue grew significantly by 32% to $35.0 million, prescription transactions revenue declined 3% to $143.1 million, and subscription revenue fell 7% to $20.5 million. The company faces headwinds from Rite Aid's bankruptcy and volume reduction in an integrated savings program, expecting a $35-40 million revenue impact in 2025. During Q2, GoodRx repurchased 10.2 million shares for $46.4 million.

For FY2025, management expects revenue growth over 2024's $792.3 million and Adjusted EBITDA between $265-275 million, representing 2-6% growth.

GoodRx (NASDAQ: GDRX), America's leading medication savings platform, has appointed Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. Jensen joins from Amazon Pharmacy, where she served as Head of Manufacturer & Prescriber Business Development, bringing extensive experience in pharmaceutical partnerships and patient access innovation.

Jensen will lead GoodRx's Pharma Manufacturer Solutions division, leveraging her background at companies like UCB and GlaxoSmithKline to enhance pharmaceutical partnerships. GoodRx, which has helped Americans save over $85 billion on medications since 2011, serves nearly 30 million consumers and over one million healthcare professionals annually.

GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025 after market close.

The company will host a conference call and webcast on Thursday, August 7, 2025 at 5:00 AM PT (8:00 AM ET) to discuss the quarterly results and business outlook. Interested participants must pre-register to receive dial-in details. The webcast will be available on the company's investor relations website, with materials posted before the call and an archived version accessible for at least 30 days afterward.

GoodRx (GDRX) has launched a new subscription service for erectile dysfunction (ED) treatment, offering an all-in-one solution starting at $18/month. The service includes virtual consultations with licensed healthcare professionals, FDA-approved prescription medications, and discreet home delivery. According to GoodRx's research, while nearly 1 in 3 U.S. men report ED issues, only 14% seek treatment due to barriers like high costs, social stigma, and inadequate insurance coverage. The new service aims to eliminate these obstacles by providing quick online consultations, often within an hour, transparent pricing with no hidden fees, and convenient home delivery in standard packaging. This initiative aligns with GoodRx's mission to make healthcare more accessible and affordable, building on their track record of helping Americans save over $85 billion on medication costs since 2011.

GoodRx (GDRX) has announced the open-source release of Lifecycle, a development tool designed to enhance software development efficiency and developer productivity. The tool, now available under the Apache 2.0 license, enables teams to create ephemeral environments for testing and code review. Lifecycle has helped GoodRx reduce deployment friction, improve collaboration, and lower infrastructure costs. The platform is hosted on GitHub under GoodRxOSS, with a new Discord community for developer support. GoodRx, a leading medication savings platform in the U.S., serves nearly 30 million consumers and over one million healthcare professionals annually, having helped Americans save over $85 billion on medication costs since 2011.

GoodRx (NASDAQ: GDRX) announced the launch of GoodRx Community Link, a new offering for independent community pharmacies, set to debut in June 2025. The platform will enable locally owned pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). The initiative implements cost-plus models to provide independent pharmacies with enhanced control over pricing and improved margins.

GoodRx, which serves nearly 30 million consumers and over 1 million healthcare professionals annually, has helped Americans save over $85 billion on medication costs since 2011. The company will host informational webinars on June 3 and 4, 2025, featuring Aaron Crittenden, President of Rx Marketplace, to discuss the new program with independent pharmacy teams.

GoodRx (NASDAQ: GDRX) reported its Q1 2025 financial results with revenue of $203.0 million, up 3% year-over-year. The company posted a net income of $11.1 million with a 5.4% margin, compared to a net loss in the previous year. Key metrics include Adjusted EBITDA of $69.8 million with a 34.4% margin. Prescription transactions revenue grew 2% to $148.9 million, while pharma manufacturer solutions revenue increased 17% to $28.6 million. The company maintained its full-year 2025 revenue guidance of $810-840 million and raised Adjusted EBITDA expectations to $273-287 million. During Q1, GoodRx repurchased 23.3 million shares for $100.9 million and ended the quarter with $301.0 million in cash and $498.8 million in debt.

GoodRx, the leading platform for medication savings in the U.S., has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on Wednesday, May 7, 2025.

A conference call and webcast with GoodRx management will follow on Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and business outlook. Interested parties can pre-register for the conference call through a provided link to receive dial-in details and a unique passcode.

The call will be webcast live on the company's investor relations website, where presentation materials will be available before the conference. An archived version of the webcast will remain accessible for at least 30 days after the call.

GoodRx (NASDAQ: GDRX) has launched a new e-commerce experience for retail pharmacies, partnering with Midwest retailer Hy-Vee as their initial collaborator. The platform enhances the prescription fulfillment process by:

The system now checks medication inventory, validates prescriptions, and enables online payment before in-store pickup. This innovation aims to streamline pharmacy workflows and improve consumer experience.

According to Wendy Barnes, President and CEO of GoodRx, this initiative addresses friction points at pharmacy counters while supporting retail pharmacy efficiency and profitability. The platform includes features like inventory verification, prescription validation, and flexible payment options including pay-over-time.

This development follows GoodRx's previous e-commerce launch with Opill, the first over-the-counter birth control pill, demonstrating the company's commitment to simplifying healthcare access. GoodRx currently serves nearly 30 million consumers and over one million healthcare professionals annually.